ATE269896T1 - Unterdrückung der abstossung bei xenotransplantation - Google Patents

Unterdrückung der abstossung bei xenotransplantation

Info

Publication number
ATE269896T1
ATE269896T1 AT99956179T AT99956179T ATE269896T1 AT E269896 T1 ATE269896 T1 AT E269896T1 AT 99956179 T AT99956179 T AT 99956179T AT 99956179 T AT99956179 T AT 99956179T AT E269896 T1 ATE269896 T1 AT E269896T1
Authority
AT
Austria
Prior art keywords
suppression
rejection
xenotransplantation
relates
cells
Prior art date
Application number
AT99956179T
Other languages
German (de)
English (en)
Inventor
Punit Satyavrat Ramrakha
Andrew John Timothy George
Dorian Haskard
Robert Ian Lechler
Anthony Imperial Colle Dorling
Original Assignee
Imp College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp College Innovations Ltd filed Critical Imp College Innovations Ltd
Application granted granted Critical
Publication of ATE269896T1 publication Critical patent/ATE269896T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/81—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the endoplasmatic reticulum [ER] or the Golgi apparatus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Control Of High-Frequency Heating Circuits (AREA)
  • Processes For Solid Components From Exhaust (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
AT99956179T 1998-11-20 1999-11-22 Unterdrückung der abstossung bei xenotransplantation ATE269896T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9825555.7A GB9825555D0 (en) 1998-11-20 1998-11-20 Suppression of xenotransplant rejection
PCT/GB1999/003888 WO2000031126A2 (en) 1998-11-20 1999-11-22 Suppression of xenotransplant rejection

Publications (1)

Publication Number Publication Date
ATE269896T1 true ATE269896T1 (de) 2004-07-15

Family

ID=10842836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99956179T ATE269896T1 (de) 1998-11-20 1999-11-22 Unterdrückung der abstossung bei xenotransplantation

Country Status (9)

Country Link
US (2) US20050255550A1 (es)
EP (1) EP1131411B1 (es)
JP (1) JP2002531072A (es)
AT (1) ATE269896T1 (es)
AU (1) AU1282900A (es)
DE (1) DE69918327T2 (es)
ES (1) ES2224713T3 (es)
GB (1) GB9825555D0 (es)
WO (1) WO2000031126A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559720A1 (en) 2004-03-17 2005-09-29 Revivicor, Inc. Tissue products derived from animals lacking any expression of functional alpha 1,3 galactosyltransferase
ES2679282T3 (es) 2004-10-22 2018-08-23 Revivicor Inc. Porcinos transgénicos que carecen de cadena ligera de inmunoglobulina endógena
WO2008153725A2 (en) 2007-05-25 2008-12-18 North Carolina State University Viral nanoparticle cell-targeted delivery platform
CN103242444A (zh) 2007-10-11 2013-08-14 大学健康网络 调节SIRPα-CD47相互作用以增加造血干细胞植入和用于此的化合物
DK2348827T3 (en) 2008-10-27 2015-07-20 Revivicor Inc IMMUNICIPLY COMPROMATED PETS
CA2757842A1 (en) * 2009-04-09 2010-10-14 The Children's Hospital Of Philadelphia Ligand-specific inhibition of attachment of immune cells to implantable biomaterials
CA2766634A1 (en) 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
AU2012217792A1 (en) 2011-02-14 2013-08-29 Revivicor, Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
JP6025067B2 (ja) * 2011-03-31 2016-11-16 ｉＨｅａｒｔ Ｊａｐａｎ株式会社 新規心筋細胞マーカー
EP2715291A4 (en) 2011-05-31 2015-10-21 Airware Inc NON-DISPERSIVE GAS SENSORS WITH ABSORPTION INFRARED ABSORPTION (NDIR)
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
EP3628047A1 (en) 2017-05-02 2020-04-01 Sanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
US20220119450A1 (en) 2019-02-04 2022-04-21 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
AU2021385081A1 (en) 2020-11-20 2023-06-29 Revivicor, Inc. Multi-transgenic pigs with growth hormone receptor knockout for xenotransplantation
EP4404740A1 (en) 2021-09-20 2024-07-31 Revivicor Inc. Multitransgenic pigs comprising ten genetic modifications for xenotransplantation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2732546B2 (ja) * 1992-09-02 1998-03-30 アイシス・ファーマシューティカルス・インコーポレーテッド 細胞接着のオリゴヌクレオチド調節
WO1996015780A1 (en) * 1994-11-23 1996-05-30 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection
JP2002514895A (ja) * 1995-09-28 2002-05-21 アレクション、ファーマスーティカルズ、インコーポレーテッド ブタ細胞相互作用タンパク質
FR2751346A1 (fr) * 1996-07-19 1998-01-23 Inst Nat Sante Rech Med Procede de preparation d'organes de mammiferes non humains transgeniques en vue de leur transplantation chez l'homme, et sequences nucleotidiques pour la mise en oeuvre de ce procede

Also Published As

Publication number Publication date
JP2002531072A (ja) 2002-09-24
WO2000031126A3 (en) 2000-08-24
AU1282900A (en) 2000-06-13
US20070157328A1 (en) 2007-07-05
DE69918327T2 (de) 2006-05-11
GB9825555D0 (en) 1999-01-13
WO2000031126A2 (en) 2000-06-02
US20050255550A1 (en) 2005-11-17
EP1131411B1 (en) 2004-06-23
ES2224713T3 (es) 2005-03-01
DE69918327D1 (de) 2004-07-29
EP1131411A2 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
ATE269896T1 (de) Unterdrückung der abstossung bei xenotransplantation
DE69937888D1 (de) Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
DE60032789D1 (de) Mikrostruktur-stentstruktur
WO2006124365A3 (en) Endothelial cell binding coatings for rapid encapsulation of bioerodable stents
WO2001077299A3 (en) A METHOD TO PREVENT GRAFT REJECTION USING TGF-β TO INDUCE T SUPPRESSOR CELLS
DE60045230D1 (de) Eingangs/Ausgangszellenanordnung für mehrere Eingangs/Ausgangsstandards
WO2002060894A3 (en) Sulfonamide lactam inhibitors of factor xa
DE60032102D1 (de) Beschichtung für einen stent
DE69922976D1 (de) Austragungsvorrichtung für implantierbare stents
DK1207904T3 (da) Nye kliniske parametre til bestemmelse af hæmatologisk toksicitet forud for radioimmunterapi
ZA985247B (en) Guanidine mimics as factor Xa inhibitors.
MA30415B1 (fr) Pale de rotor pour centrale electrique eolienne
DE59814262D1 (de) Wandler für teil- oder vollimplantierbare Hörgeräte
DE59814473D1 (de) Wandleranordnung für teil- oder vollimplantierbare Hörgeräte
DK1773420T3 (da) Anvendelse af gingivale fibroblaster til vaskulær celleterapi
TR200101704T2 (tr) Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı
TR200003323T2 (tr) Geniş-tesir sahalı mantar önleyiciler olarak suda eriyebilir azoller
DE69917554D1 (de) Kathodisches Aktivmaterial für Lithium-Akkumulator
ATE410707T1 (de) Kovalent gebundene, hydrophile beschichtungszusammensetzungen für implantate
WO2004044127A3 (en) Stem cell populations
HK1060855A1 (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment ofdelayed graft function
EA200300468A1 (ru) Подавление зависимости опухолевых клеток от фактора роста
ATE248709T1 (de) Verbundelemente
DE60023034D1 (en) Cd45 hemmer
MXPA03001986A (es) Composiciones antitromboticas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1131411

Country of ref document: EP

REN Ceased due to non-payment of the annual fee